Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Creative Planning

Creative Planning lessened its holdings in shares of Xencor, Inc. (NASDAQ:XNCR) by 21.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 12,095 shares of the biopharmaceutical company’s stock after selling 3,260 shares during the quarter. Creative Planning’s holdings in Xencor were worth $243,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Texas Permanent School Fund Corp increased its position in shares of Xencor by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 53,277 shares of the biopharmaceutical company’s stock valued at $1,179,000 after purchasing an additional 690 shares during the period. Linden Thomas Advisory Services LLC boosted its position in shares of Xencor by 1.6% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company’s stock valued at $826,000 after purchasing an additional 699 shares in the last quarter. Baillie Gifford & Co. grew its stake in shares of Xencor by 3.3% in the 2nd quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock worth $445,000 after purchasing an additional 744 shares during the last quarter. Louisiana State Employees Retirement System increased its holdings in shares of Xencor by 3.0% in the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 900 shares in the last quarter. Finally, Diversified Trust Co raised its position in shares of Xencor by 7.8% during the second quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 1,017 shares during the period.

Analyst Ratings Changes

Several research analysts have commented on the stock. JPMorgan Chase & Co. raised their target price on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday. BMO Capital Markets reissued an “outperform” rating and set a $34.00 target price (up from $32.00) on shares of Xencor in a research note on Friday. Wedbush reaffirmed an “outperform” rating and issued a $38.00 target price on shares of Xencor in a research report on Thursday. Finally, Royal Bank of Canada upped their price target on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $35.75.

Xencor Trading Up 1.9 %

Xencor stock opened at $23.62 on Monday. Xencor, Inc. has a 12 month low of $15.31 and a 12 month high of $26.84. The company has a quick ratio of 6.92, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.65 billion, a P/E ratio of -7.38 and a beta of 0.66. The company’s fifty day simple moving average is $20.45 and its 200-day simple moving average is $20.29.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $10.70 million during the quarter, compared to analysts’ expectations of $14.59 million. During the same quarter last year, the firm earned ($0.40) earnings per share. The business’s revenue for the quarter was down 81.9% on a year-over-year basis. As a group, sell-side analysts forecast that Xencor, Inc. will post -3.91 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.